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Summary Varicella zoster virus (VZV) infection may trigger Guillain—Barre´ syndrome (GBS),
but this is rare and almost always in the context of reactivation disease from latent VZV,
‘shingles’. We report here a case of severe GBS following primary VZV infection in an adult. A
40-year-old man of Indian origin developed features of GBS including quadriplegia, bulbar
paralysis, and bilateral facial nerve palsies 14 days after primary VZV infection contracted from
a known case in a family member. Nerve conduction studies confirmed acute inflammatory
demyelinating polyneuropathy. Anti-ganglioside antibodies were negative. The mechanism of
Schwann cell attack following VZV infection is poorly understood but this case suggests that
primary VZV infection may be a sufficient stimulus to drive antibody generation and precipitate
severe clinical symptomatology. Themorbidity associated with the complications of VZV infection
in adulthood could be avoided if patients who are seronegative for VZV (frequently from the Asian
subcontinent) are offered prophylaxis after an exposure in adulthood.
# 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
Guillain—Barre´ syndrome (GBS) usually occurs as a post-
infective immune-mediated phenomenon. Many precipitants
have been recognized and it is known that varicella zoster
virus (VZV) infection may trigger GBS. However this is rare;
fewer then 50 such cases have been reported in the litera-
ture, and, when it does occur, it is almost always in the
context of reactivation disease from latent VZV, following
herpes zoster (‘shingles’). We report here a case of severe
GBS following primary VZV infection (‘chickenpox’).* Corresponding author. Tel.: +44 7799605069.
E-mail address: fionacresswell@doctors.org.uk (F. Cresswell).
1201-9712/$36.00 # 2009 International Society for Infectious Diseases.
doi:10.1016/j.ijid.2009.03.019Case report
A 40-year-old man, UK-resident but of Indian origin, pre-
sented with a 4-day history of cough, fever, and widespread
vesicular rash. His 14-year-old son had recently had clinically
confirmed chickenpox. The patient had no history of chick-
enpox in childhood. On examination he had a widespread
vesicular/pustular rash typical of chickenpox; the rash was
extensive and severe. Primary VZV infection was diagnosed
and he was treated with a single dose of acyclovir (10 mg/kg
intravenously), followed by valacyclovir (1 g three times
daily orally for 7 days). The patient initially made a good
recovery; his rash, respiratory and systemic symptoms all
improved over the next week.Published by Elsevier Ltd. All rights reserved.
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oped a tingling sensation in his lower extremities, leg
weakness, and an unsteady gait. The following day this
progressed to a left-sided facial droop and slurred speech
and he was re-admitted. At this time he was afebrile, had a
normal respiratory rate, 100% saturation on air, and was
normotensive, although slightly tachycardic (sustained at
around 100 bpm). Over the subsequent 24 hours his neu-
rological deficit progressed rapidly; he developed bilateral
complete VIIth nerve palsies and reduced power in sterno-
cleidomastoids and trapezii bilaterally; speech was slurred
and his swallow was impaired. Muscle tone was globally
decreased with weakness, worst in the proximal upper
limbs (upper limbs: 2/5 proximally, 4-/5 distally; lower
limbs: 4/5, proximal and distal). Reflexes were absent but
sensation intact.
Investigations revealed a normal computed tomography
scan of the brain and magnetic resonance imaging scan of the
brain and spinal cord. The cerebrospinal fluid (CSF) was
acellular and glucose normal, but CSF protein was high
(1.0 g/l). CSF-PCR for VZV DNA was negative. Nerve conduc-
tion studies showed increased latency and decreased ampli-
tudes. Motor nerve velocities in the left ulnar, right lateral
popliteal, and right median were 43, 45, and 36 m/s, respec-
tively, and sensory velocities in the right sural nerve, 48 m/s,
findings suggestive of an acute inflammatory demyelinating
polyneuropathy.
Post-VZV GBS was diagnosed and treatment with intrave-
nous immunoglobulin (Vigam 0.4 mg/kg/day, for 5 days)
commenced. He required nasogastric feeding and his vital
capacity fell to 0.2 l with a brief episode of tachycardia of 110
bpm. He did not begin to improve clinically until approxi-
mately 10 days after onset of his neurological symptoms.
Subsequently, he made a full recovery of power in his arms
and legs, but two months on is still receiving speech and
language therapy, as his facial nerve palsies and speech have
been slower to improve.
Discussion
This patient has all the cardinal clinical features of GBS;
weakness, paresthesias, and diminished or absent deep ten-
don reflexes.1 Typically, nerve conduction studies often show
slowing and decreased amplitude, as in this case (although
they may be normal). CSF protein is typically raised, as in this
patient, reported ranges being 0.5—3.0 g/l.2 VZV, however, is
a rare antecedent for GBS. In a study examining antecedent
infections in GBS, Jacobs et al. found only one case out of 154
that could be attributed to VZV.3 Of the fewer than 50
reported cases in the literature, only six involved primary
infection and of these none involved adults.4—7 GBS following
herpes zoster typically has a latent period of two weeks to
two months. Shorter latent periods, as in this case, are
associated with more severe illness.8
Immigrants to Europe and America are at risk of acquir-
ing adult VZV infection as infection in childhood is less
frequent in the Asian subcontinent.9 Seronegative patients
exposed to the virus may avoid symptomatic illness by
taking prophylactic antiviral therapy. A one-week course
of acyclovir at treatment doses, starting one week after
exposure to VZV allows a virema and seroconversion, but
may prevent systemic and neurological disease, thus avoid-ing the heightened morbidity associated with VZV infection
in adulthood.10,11
In GBS, two distinct pathophysiological patterns are
observed. The demyelinating pattern predominates in
North America and Europe, whereas axonal variants occur
more frequently in China.12 The electrophysiology in this
patient suggests that he experienced a demyelinating
pattern. Certain subtypes of GBS are associated with anti-
bodies to gangliosides. Antibodies to the ganglioside GQ1b
are virtually pathognomonic of the Miller Fisher variant of
GBS (which presents with a descending paralysis) and
antibodies to GM-1 and GD1a occur frequently in acute
motor axonal neuropathy (AMAN).13 There are cases of
anti-ganglioside antibodies in association with acute
inflammatory demyelinating polyneuropathy (AIDP), but
in general anti-ganglioside antibodies appear to be less
frequently associated with AIDP than with AMAN.14,15 In
this case of AIDP the anti-GM1, anti-GM2, and anti-GQ1b
were negative. This suggests there is an alternative
mode of pathogenesis in AIDP, which is currently poorly
understood.
It is thought that the well-described association of GBS
with Campylobacter jejuni infection arises because the lipo-
polysaccharides of these organisms contain epitopes that are
similar to peripheral nerve gangliosides. They act as ‘mole-
cular mimics’, driving production of antibodies with anti-
ganglioside specificity, which result in injury to peripheral
nerve fibers.12 In AIDP the attack appears to be directed to a
component of the Schwann cell, but the precise nature of
antigenic targets is still not clear.16 Whether a similar ‘mole-
cular mimicry’ occurs with post-VZV GBS remains specula-
tive. Such antibody generation may occur at higher titers and
more frequently in the secondary response associated with
VZV reactivation (shingles), but this case suggests that pri-
mary VZV infection per se may sometimes be a sufficient
stimulus to drive antibody generation and precipitate severe
clinical symptomatology.
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